Mechanisms of drug resistance in mycobacterium tuberculosis

Frontiers in Bioscience

Volumn 9, Issue , 2004, Pages 975-994

  Wade, Mary Margaret ^a   Zhang, Ying ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Anti Tuberculosis Drugs; Bacterium; Disease; Infection; Mechanisms of Resistance; Microorganisms; Mycobacterium Tuberculosis; Review; Tuberculosis

Indexed keywords

AMIKACIN; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; DRUG INFORMATION; MEDICAL INFORMATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; REVIEW; ANIMAL; DRUG EFFECT; HUMAN; MULTIDRUG RESISTANCE; PHYSIOLOGY;

BACILLI; BACTERIA (MICROORGANISMS); MYCOBACTERIUM; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS;

EID: 2542475123     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1289     Document Type: Review

References (202)

1. Dye, C., S. Scheele, P. Dolin, V. Pathania & M. C. Raviglione: Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA 282, 677-686 (1999)
2. Zhang, Y., B. Heym, B. Allen, D. Young & S. Cole: The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 358, 591-593 (1992)
3. Telenti, A., P. Imboden, F. Marchesi, D. Lowrie, S. T. Cole, M. J. Colston, L. Matter, K. Schopfer & T. Bodmer: Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341, 647-650 (1993)
4. Finken, M., P. Kirschner, A. Meier, A. Wrede & E. C. Bottger: Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: alteration of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot. Mol. Microbiol 9, 1239-1246 (1993)
5. Nair, J., D. Rouse, G. H. Bai & D. Morris: The rpsL gene and streptomycin resistance in single and multiple drug-resistant strains of Mycobacterium tuberculosis. Mol Micrbiol 10, 521-527 (1993)
6. Honore, N. & S. T. Cole: Streptomycin resistance in mycobacteria. Antimicrob Agents Chemother 38, 238-242 (1994)
7. Banerjee, A., E. Dubnau, A. Quemard, V. Balasubramanian, S. K. Um, T. Wilson, D. Collins, G. De Lisle & W. R. Jacobs, Jr.: inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263, 227-230 (1994)
8. Scorpio, A. & Y. Zhang: Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 2, 662-667 (1996)
9. Belanger, A. E., G. S. Besra, M. E. Ford, K. Mikusova, J. T. Belisle, P. J. Brennan & J. M. Inamine: The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc Natl Acad Sci USA 93, 11919-24 (1996)
10. Telenti, A., W. Phillipp, S. Sreevatsan, C. Bernasconi, K. E. Stockbauer, B. Wieles, J. M. Musser & W. R. Jacobs, Jr.: The emb operon, a unique gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat Med 3, 567-570 (1997)
11. Y Zhang & A Telenti: Genetics of drug resistance in Mycobacterium tuberculosis. In: Molecular genetics of mycobacteria. Eds: Hatfull G, Jacobs W R, AMS Press, Washington D.C. 235-254 (2000)
12. Davies, J.: Antibiotic resistance in mycobacteria. Novartis Found Symp 217, 195-208 (1998)
13. Ramaswamy, S., & J. M. Musser: Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 79, 3-29 (1998)
14. Riska, P. F., W. R. Jacobs, Jr, & D. Alland: Molecular determinants of drug resistance in tuberculosis. Int J Tuberc Lung Dis 4, (2 Suppl 1):S4-10 (2000)
15. Heym, B., W. Philipp, & S. T. Cole: Mechanisms of drug resistance in Mycobacterium tuberculosis. Curr Top Microbiol Immunol 215, 49-69 (1996)
16. Somoskovi, A., L. M. Parsons, & M. Salfinger: The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respir Res 2, 164-8 (2001)
17. Jarlier, V. & H. Nikaido: Mycobacterial cell wall: structure and role in natural resistance to antibiotics. FEMS Microbiol Lett 15, 123(1-2):11-8 (1994)
18. Kwon, H. H., H. Tomioka, & H. Saito: Distribution and characterization of β-lactamases of mycobacteria and related organisms. Tuberc Lung Dis 76, 141-148 (1995)
19. Segura, C., M. Salvado, I. Collado, J. Chaves & A. Coira: Contribution of beta-lactamases to beta-lactam susceptibilities of susceptible and multidrug-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 42, 1524-6 (1998)
20. Cole, S. T., et al.: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393, 537-544 (1998)
21. Heym, B., N. Honore, C. Truffot-Pernot, A. Banerjee, C. Schurra, W. R. Jacobs, Jr., J. D. A. van Embden, J. H. Grosset, & S. T. Cole: implications of multidrug resistance for the future of short course chemotherapy of tuberculosis: a molecular study. Lancet 344, 293-298 (1994)
22. Crawford, J. T., M. D. Cave & J. H. Bates: Characterization of plasmids from strains of Mycobacterium avium-intracellulare. Rev Infect Dis 3, 949-52 (1981)
23. Martin, C., J. Timm, J. Rauzier, R. Gomez-Lus, J. Davies & B. Gicquel: Transposition of an antibiotic resistant element in mycobacteria. Nature 345, 739-743 (1990)
24. rd & V. Mizrahi: DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycohacterium tuberculosis. Cell 18, 183-93 (2003)
25. nd ed. Eds: Rom W N, Garay S M, Lippincott Williams & Wilkins, A Wolters Kluwer Company, New York. 739-758 (2003)
26. Miesel, L., D. A. Rozwarski, J. C. Sacchettini & W. R. Jacobs Jr.: Mechanisms for isoniazid action and resistance. Novartis Found Symp 217, 209-21 (1998)
27. Slayden, R. A. & C. E. Barry 3rd.: The genetics and biochemistry of isoniazid resistance in Mycobacterium tuberculosis. Microbes Infect 2, 659-69 (2000)
28. Heym, B., B. Saint-Joanis & S. T. Cole: The molecular basis of isoniazid resistance in Mycobacterium tuberculosis. Tuber Lung Dis 79, 267-71 (1999)
29. Mitchison, D. A. & J. B. Selkon: The bactericidal activities of antituberculosis drugs. Am Rev Tuberc, 74, 109-116 (1956)
30. Barclay, W. R., R. H. Ebert, & D. Koch-Weser: Mode of action of isoniazid. Am Rev Tuberc, 67, 490-496 (1953)
31. Johnsson, K. & P. G. Schultz: Mechanistic studies of the oxidation of isoniazid by the catalase-peroxidase from Mycobacterium tuberculosis. J Am Chem Soc 116, 7425-7426 (1994)
32. Johnsson, K., D. S. King & P. G. Schultz: Studies on the mechanism of action of isoniazid and ethionamide in the chemotherapy of tuberculosis. J Am Chem Soc 117, 5009-5010 (1995)
33. Magliozzo, R. S. & J. A. Marcinkeviciene: Evidence for isoniazid oxidation by oxyferrous mycobacterial catalase-peroxidase. J Am Chem Soc 118, 11303-11304 (1996)
34. Wengenack, N. L. & F. Rusnak: Evidence for isoniazid-dependent free radical generation catalyzed by Mycobacterium tuberculosis KatG and the isoniazid-resistant mutant KatG(S315T). Biochemistry 40, 8990-8996 (2001)
35. Lei, B., C. J. Wei & S. C. Tu: Action mechanism of antitubercular isoniazid. Activation by Mycobacterium tuberculosis KatG, isolation, and characterization of InhA inhibitor. J Biol Chem, 275, 2520-2526 (2000)
36. Chouchane, S., I. Lippai & R. S. Magliozzo: Catalase-peroxidase (Mycobacterium tuberculosis KatG) catalysis and isoniazid activation. Biochemistry 39, 9975-9983 (2000)
37. Broussy, S., Y. Coppel, M. Nguyen, J. Bernadou & B. Meunier: 1H and 13C NMR characterization of hemiamidal isoniazid-NAD(H) adducts as possible inhibitors of InhA reductase of Mycobacterium tuberculosis. Chemistry 9, 2034-8 (2003)
38. Rozwarski, D. A., G. A. Grant, D. H. Barton, W. R. Jacobs, Jr. & J. C. Sacchettini: Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 279, 98-102 (1998)
39. Shoeb, H. A., B. U. Bowman Jr., A. C. Ottolenghi, et al.: Evidence for the generation of active oxygen by isoniazid treatment of extracts of Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother 27, 404-407 (1985)
40. Shoeb, H. A., B. U. Bowman Jr., A. C. Ottolenghi, et al.: Evidence for the generation of active oxygen by isoniazid treatment of extracts of Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother 27, 408-412 (1985)
41. Magliozzo, R. S. & J. A. Marcinkeviciene: The role of Mn(II)-peroxidase activity of mycobacterial catalase-peroxidase in activation of the antibiotic isoniazid. J Biol Chem 272, 8867-70 (1997)
42. Quemard, A., J. C. Sacchettini, A. Dessen, C. Vilcheze, R. Bittman, W. R. Jacobs, Jr. & J. S. Blanchard: Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis. Biochemistry 34, 8235-41 (1995)
43. Quémard, A., A. Dessen, M. Sugantino, et al.: Binding of catalase-peroxidase-activated isoniazid to wild-type and mutant Mycobacterium tuberculosis enoyl-ACP reductases. J Am Chem Soc 118, 1561-1562 (1996)
44. McMurry, L. M., P. F. McDermott & S. B. Levy: Genetic evidence that InhA of Mycobacterium smegmatis is a target for triclosan. Antimicrob Agents Chemother 43, 711-3 (1999)
45. Parikh, S. L., G. Xiao & P. J. Tonge: Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid. Biochemistry 39, 7645-50 (2000)
46. Dessen, A., A. Quemard, J. S. Blanchard, et al.: Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis. Science 267, 1638-1641 (1995)
47. Basso, L. A., R. Zheng, J. M. Musser, et al.: Mechanisms of isoniazid resistance in Mycobacterium tuberculosis: enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates. J Infect Dis 178, 769-775 (1998)
48. Ito, K. K., K. Yamamoto & S. Kawanishi: Manganese-mediated oxidative damage of cellular and isolated DNA by isoniazid and related hydrazines: non-Fenton-type hydroxyl radical formation. Biochemistry 31, 11606-11613 (1992)
49. F G Winder: Mode of action of the antimycobacterial agents and associated aspects of the molecular biology of mycobacteria. In: The biology of mycobacteria (Vol I). Eds: Ratledge C, Stanford J, Academic Press, New York 354-438 (1982)
50. Zatman, L. J., N. O. Kaplan, S. P. Colowick, et al.: Effect of isonicotinic acid hydrazide on diphosphopyridine nucleotidases. J Biol Chem 209, 453-484 (1954)
51. Bekierkunst, A.: Nicotinamide-adenine dinucleotide in tubercle bacilli exposed to isoniazid. Science 152, 525-526 (1966)
52. Wei, C. J., B. Lei, J. M. Musser & S. C. Tu: Isoniazid activation defects in recombinant Mycobacterium tuberculosis catalase-peroxidase (KatG) mutants evident in InhA inhibitor production. Antimicrob Agents Chemother 47, 670-5 (2003)
53. Zhang, Y., A. Scorpio, H. Nikaido & Z. Sun: Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Bacteriol 181, 2044-2049 (1999)
54. Youatt, J.: The uptake of isoniazid by washed cell suspension of mycobacteria and other bacteria. Aust J Exp Biol Med Sci 36, 223-233 (1958)
55. Choudhuri, B. S., S. Sen & P. Chakrabarti: Isoniazid accumulation in Mycobacterium smegmatis is modulated by proton motive force-driven and ATP-dependent extrusion systems. Biochem Biophys Res Comm 256, 682-684 (1999)
56. Wilson, M., J. DeRisi, H. H. Kristensen, et al.: Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization. Proc Natl Acad Sci USA 96, 12833-12838 (1999)
57. Milano, A., E. De Rossi, L. Gusberti, et al.: The katE gene, which encodes the catalase HPII of Mycobacterium avium. Mol Microbiol 19:113-123 (1996)
58. Rosner, J. L.: Susceptibility of oxyR regulon mutants of Escherichia coli and Salmonella typhimurium to isoniazid. Antimicrob Agents Chemother 37, 2251-2253 (1993)
59. Rosner, J. L. & G. Storz: Effects of peroxides on susceptibilities of Escherichia coli and Mycobacterium smegmatis to isoniazid. Antimicrob Agents Chemother 38, 1829-1833 (1994)
60. Dhandayuthapani, S., Y. Zhang, M. H. Mudd & V. Deretic: Oxidative stress response and its role in sensitivity to isoniazid in mycobacteria: characterization and inducibility of ahpC by peroxides in Mycobacterium smegmatis and lack of expression in M. aurum and M. tuberculosis. J Bacteriol 178, 3641-9 (1996)
61. rd & C. K. Stover: Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science 272, 1641-3 (1996)
62. Wilson, T. M. & D. M. Collins: ahpC, a gene involved in isoniazid resistance of the Mycobacterium tuberculosis complex. Mol Microbiol 19, 1025-1034 (1996)
63. Sherman, D. R., K. Mdluli, M. J. Hickey, et al.: Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science 272, 1641-1643 (1996)
64. Payton, M., R. Auty, R. Delgoda, et al.: Cloning and characterization of arylamine N-acetyltransferase genes from Mycobacterium smegmatis and Mycobacterium tuberculosis: increased expression results in isoniazid resistance. J Bacteriol 181, 1343-1347 (1999)
65. Upton, A. M., A. Mushtaq, T. C. Victor, et al.: Arylamine N-acetyltransferase of Mycobacterium tuberculosis is a polymorphic enzyme and a site of isoniazid metabolism. Mol Microbiol 42, 309-317 (2001)
66. Middlebrook, G.: Isoniazid resistance and catalase activity of tubercle bacilli. Am Rev Tuberc 69, 471-472 (1954)
67. Zhang, Y., T. Garbe & D. Young: Transformation with katG restores isoniazid sensitivity in Mycobacterium tuberculosis isolates resistant to a range of drug concentrations. Mol Microbiol 8, 521-524 (1993)
68. G Meissner: The bacteriology of the tubercle bacillus. In: Chemotherapy of tuberculosis. Eds: Barry V C, Butterworths, London 65-109 (1964)
69. Wilson, T. M., G. W. de Lisle & D. M. Collins: Effect of inhA and katG on isoniazid resistance and virulence of Mycobacterium bovis. Mol Microbiol 15, 1009-15 (1995)
70. Li, Z., C. Kelley, F. Collins, D. Rouse & S. Morris: Expression of katG in Mycobacterium tuberculosis is associated with its growth and persistence in mice and guinea pigs. J Infect Dis 177, 1030-5 (1998)
71. Heym, B., P. M. Alzari, N. Honore, et al.: Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol Microbiol 15, 235-245 (1995)
72. Rouse, D. A., Z. Li, G. H. Bai & S. L. Morris: Characterization of the katG and inhA genes of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 39, 2472-2477 (1995)
73. Rouse, D. A. & S. L. Morris: Molecular mechanisms of isoniazid resistance in Mycobacterium tuberculosis and Mycobacterium bovis. Infect Immun 63, 1427-1433 (1995)
74. Musser, J. M., V. Kapur, D. L. Williams, et al.: Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. J Infect Dis 173, 196-202 (1996)
75. Dobner, P., S. Rusch-Gerdes, G. Bretzel, K. Feldmann, M. Rifai, T. Loscher & H. Rinder: Usefulness of Mycobacterium tuberculosis genomic mutations in the genes katG and inhA for the prediction of isoniazid resistance. Int J Tuberc Lung Dis 1, 365-9 (1997)
76. Marttila, H. J., H. Soini, E. Eerola, et al.: A Ser315Thr substitution in KatG is predominant in genetically heterogeneous multidrug-resistant Mycobacterium tuberculosis isolates originating from the St. Petersburg area in Russia. Antimicrob Agents Chemother, 42, 2443-2445 (1998)
77. van Soolingen, D., P. E. de Haas, H. R. van Doorn, et al.: Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands. J Infect Dis 182, 1788-1790 (2000)
78. Banerjee, A., M. Sugantino, J. C. Sacchettini & W. R. Jacobs, Jr.: The mabA gene from the inhA operon of Mycobacterium tuberculosis encodes a 3-ketoacyl reductase that fails to confer isoniazid resistance. Microbiology 144, 2697-704 (1998)
79. rd: Inhibition of Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid. Science 280, 1607-1610 (1998)
80. Lee, A. S., I. H. Lim, L. L. Tang, A. Telenti & S. Y. Wong: Contribution of kasA analysis to detection of isoniazid-resistant Mycobacterium tuberculosis in Singapore. Antimicrob Agents Chemother 43, 2087-9 (1999)
81. Piatek, A. S., A. Telenti, M. R. Murray, H. El-Hajj, W. R. Jacobs, Jr., F. R. Kramer & D. Alland: Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapid susceptibility testing. Antimicrob Agents Chemother 44, 103-10 (2000)
82. Larsen, M. H., C. Vilcheze, L. Kremer, G. S. Besra, L. Parsons, M. Salfinger, L. Heifets, M. H. Hazbon, D. Alland, J. C. Sacchettini & W. R. Jacobs, Jr.: Overexpression of inhA, but not has A, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis. Molec Microbiol 46, 453-466 (2002)
83. Kremer, L., L. G. Dover, H. R. Morbidoni, C. Vilcheze, W. N. Maughan, A. Baulard, S. C. Tu, N. Honore, V. Deretic, J. C. Sacchettini, C. Locht, W. R. Jacobs, Jr. & G. S. Besra: Inhibition of InhA activity, but not KasA activity, induces formation of a KasA-containing complex in mycobacteria. J Biol Chem 278, 20547-54 (2003)
84. Miesel, L., T. Weisbrod, J. A. Marcinkeviciene, R. Bittman, P. Doshi, J. C. Sacchettini & W. R. Jacobs, Jr.: NADH dehydrogenase defects confer resistance to isoniazid and conditional lethality in Mycobacterium smegmatis. J Bacteriol 180, 2459-2467 (1998)
85. Lee, A. S. G., A. S. M. Teo & S. Y. Wong: Novel mutations in ndh in isoniazid-resistant Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 45, 2157-2159 (2001)
86. Wilson, T. M. & D. M. Collins: ahpC, a gene involved in isoniazid resistance of the Mycobacterium tuberculosis complex. Mol Microbiol 19, 1025-1034 (1996)
87. Heym, B., E. Stavropoulos, N. Honore, et al.: Effects of overexpression of the alkyl hydroperoxide reductase AhpC on the virulence and isoniazid resistance of Mycobacterium tuberculosis. Infect Immun 65, 1395-1401 (1997)
88. Telenti, A., N. Honore, C. Bernasconi, et al.: Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: A blind study at reference laboratory level. J Clin Microbiol 35, 719-723 (1997)
89. Alland, D., I. Kramnik, T. R. Weisbrod, L. Otsubo, L. P. Miller, W. R. Jacobs, Jr. & B. R. Bloom: Identification of differentially expressed mRNA in prokaryotic organisms by customized amplification libraries (DECAL): the effect of isoniazid on gene expression in Mycobacterium tuberculosis. Proc Nat Acad Sci USA 22, 13227-13232 (1998)
90. Wilson, M., J. DeRisi, H. H. Kristensen, P. Imboden, S. Rane, P. O. Brown & G. K. Schoolnik: Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization. Proc Natl Acad Sci U S A 96, 12833-8 (1999)
91. Ramaswamy, S. V., R. Reich, S. J. Dou, L. Jasperse, X. Pan, A. Wanger, T. Quitugua & E. A. Graviss: Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 47, 1241-50 (2003)
92. Mitchison, D.: The action of antituberculosis drugs in short course chemotherapy. Tubercle 66, 219-225 (1985)
93. nd ed. Eds: Rom W N, Garay S M, Lippincott Williams & Wilkins, A Wolters Kluwer Company, New York. 759-772 (2003)
94. Mitchison, D. A. & A. J. Nunn: Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 133, 423-430 (1986)
95. Bodmer, T., G. Zurcher, I. Imboden & A. Telenti: Molecular basis of rifabutin susceptibility in rifampicin resistant M. tuberculosis. J Antimicrob Chemother 35, 345-348 (1995)
96. Moghazeh, S. L., X. Pan, T. Arain, C. K. Stover, J. M. Musser & B. N. Kreiswirth: Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob Agents Chemother 40, 2655-2657 (1996)
97. Williams, D., L. Spring, L. Collins, L. P. Miller, L. Heifets, P. R. Gangadharam & T. P. Gillis: Contribution of rpoB mutation to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 42, 1853-1857 (1998)
98. Dabbs, E. R., K. Yazawa, Y. Mikami, M. Miyaji, N. Morisaki, S. Iwasaki & K. Furihata: Ribosylation by mycobacterial strains as a new mechanism of rifampin inactivation. Antimicrob Agents Chemother 39, 1007-1009 (1995)
99. Quan, S., H. Venter & E. R. Dabbs: Ribosylative inactivation of rifampin by Mycobacterium smegmatis is a principal contributor to its low susceptibility to this antibiotic. Antimicrob Agents Chemother 41, 2456-2460 (1997)
100. Tarshis, M. S. & W. A. Weed: Lack of significant in vitro sensitivity of Mycobacterium tuberculosis to pyrazinamide on three different solid media. Am Rev Tuberc 67, 391-395 (1953)
101. McDermott, W. & R. Tompsett: Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am Rev Tuberc 70, 748-754 (1954)
102. S H Siddiqi: Antimicrobial susceptibility testing: radiometric (BACTEC) tests for slowly growing mycobacteria. In: Clinical Microbiology Procedure Handbook. Eds: Isenberg H D, ASM Press, Washington D.C. 14-25 (1992)
103. Zhang, Y. & D. Mitchison: The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 7, 6-21 (2003)
104. Salfinger, M. & L. B. Heifets: Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method. Antimicrob Agents Chemother 32, 1002-4 (1988)
105. Zhang, Y., S. Permar & Z. Sun: Conditions that may affect the results of Mycobacterium tuberculosis susceptibility testing to pyrazinamide. J Med Microbiol 51, 42-49 (2002)
106. Heifets, L. B. & P. J. Lindholm-Levy: Is pyrazinamide bactericidal against Mycobacterium tuberculosis? Am Rev Respir Dis 141, 250-252 (1990)
107. Rastogi, N., M. C. Potar & H. L. David: Pyrazinamide is not effective against intracellularly growing Mycobacterium tuberculosis. Antimicrob Agents Chemother 32, 287 (1988)
108. Heifets, L., M. Higgins & B. Simon: Pyrazinamide is not active against Mycobacterium tuberculosis residing in cultured human monocyte-derived macrophages. Int J Tuberc Lung Dis 4, 491-495 (2000)
109. Crowle, A. J., J. A. Sbarbaro & M. H. May: Inhibition by pyrazinamide of tubercle bacilli within cultured human macrophages. Am Rev Respir Dis 134, 1052-5 (1986)
110. McCune, R. M., R. Tompsett & W. McDermott: The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by administration of pyrazinamide and a companion drug. J Exp Med 104, 763-802 (1956)
111. Cynamon, M. H. & M. Sklaney: Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis. Antimicrob Agents Chemother 47, 2442-4 (2003)
112. Harvel, A., L. Trnka & J. Kuska: Comparison of the antituberculous activity of morphazinamide and pyrazinamide on chronic experimental tuberculosis. II. The emergence of resistance and its retardation in the course of treatment by single drugs and by combination of antituberculous drugs. Chemotherapia (Basel) 9, 168-175 (1964)
113. Zhang, Y., Wade, M.M., Scorpio, A. Zhang, H. & Z. Sun: Mode of action of pyrazinamide: Disruption of membrane potential and transport by pyrazinamide. J Antimicrob Chemother In Press.
114. Yeager, R. L., W. G. Munroe & F. I. Dessau: Pyrazinamide (Aldinamide) in the treatment of pulmonary tuberculosis. Am Rev Tuberc 65, 523-534 (1952)
115. Konno, K., F. M. Feldman & W. McDermont: Pyrazinamide susceptibility and amidase activity of the tubercle bacilli. Am Rev Respir Dis 95, 461-469 (1967)
116. Zimhony, O., J. S. Cox, J. T. Welch, C. Vilcheze & W. R. Jacobs, Jr.: Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FAS-I) of Mycobacterium tuberculosis. Nature Med 6, 1043-1047 (2000)
117. rd: Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I. J Bacteriol 184, 2167-2172 (2002)
118. Scorpio, A., P. Lindholm-Levy, L. Heifets, R. Gilman, S. Siddiqi, M. Cynamon & Y. Zhang: Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 41, 540-543 (1997)
119. Kasarov, L. B. & A. G. Moat: Metabolism of nicotinamide adenine dinucleotide in human and bovine strains of Mycobacterium tuberculosis. J Bacteriol 110, 600-603 (1972)
120. J W Foster & Moat AG: Microbial Physiology, Third edition. John Wiley & Sons, New York (1995)
121. Dimroth, P., G. Kaim & U. Matthey: Crucial role of the membrane potential for ATP synthesis by F(1)F(o) ATP synthases. J Exp Biol 203, 51-9 (2000)
122. Zhang, Y., H. Zhang & Z. Sun: Susceptibility of Mycobacterium tuberculosis to weak acids. J Antimicrob Chemother. 52, 56-60 (2003)
123. McClatchy, J. K., A. Y. Tsang & M. S. Cernish: Use of pyrazinamidase activity in Mycobacterium tuberculosis as a rapid method for determination of pyrazinamide susceptibility. Antimicrob Agents Chemother 20, 556-557 (1981)
124. Butler, W. R. & J. O. Kilburn: Susceptibility of Mycobacterium tuberculosis to pyrazinamide and its relationship to pyrazinamidase activity. Antimicrob Agents Chemother 24, 600-601 (1983)
125. Trivedi, S. S. & S. G. Desai: Pyrazinamidase activity of Mycobacterium tuberculosis - a test of sensitivity to pyrazinamide. Tubercle 68, 221-224 (1987)
126. Miller, M., L. Thibert, F. Desjardins, S. Siddiqi & A. Dascal: Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide: comparison of Bactec method with pyrazinamidase assay. J Clin Microbiol 33, 2468-2470 (1995)
127. Cheng, S. J., L. Thibert, T. Sanchez, L. Heifets & Y. Zhang: pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada. Antimicrob Agents Chemother 44, 528-32 (2000)
128. Sreevatsan, S., X. Pan, Y. Zhang, B. N. Kreiswirth & J. M. Musser: Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms. Antimicrob Agents Chemother 41, 636-40 (1997)
129. Hirano, K., M. Takahashi, Y. Kazumi, Y. Fukasawa & C. Abe: Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis. Tuber Lung Dis 78, 117-22 (1997)
130. Sachais, B. S., I. I. Nachamkindagger, J. K. Mills & D. G. Leonard: Novel pncA mutations in pyrazinamide-resistant isolates of Mycobacterium tuberculosis. Mol Diagn 3, 229-231 (1998)
131. Hoashi, S., H. Tai & M. Tamari: pncA gene mutations in clinical isolates of tubercle bacillus by polymerase chain reaction-direct sequencing method: in relationship to pyrazinamide resistance. Kekkaku 74, 441-445 (1999)
132. Mestdagh, M., P. A. Fonteyne, L. Realini, R. Rossau, G. Jannes, W. Mijs, K. A. De Smet, F. Portaels & E. Van den Eeckhout: Relationship between pyrazinamide resistance, loss of pyrazinamidase activity, and mutations in the pncA locus in multidrug-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 43, 2317-9 (1999)
133. Marttila, H. J., M. Marjamaki, E. Vyshnevskaya, B. I. Vyshnevskiy, T. F. Otten, A. V. Vasilyef & M. K. Viljanen: pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from northwestern Russia. Antimicrob Agents Chemother 43, 1764-6 (1999)
134. Lemaitre, N., W. Sougakoff, C. Truffot-Pernot & V. Jarlier: Characterization of new mutations in pyrazinamide-resistant strains of Mycobacterium tuberculosis and identification of conserved regions important for the catalytic activity of the pyrazinamidase pncA. Antimicrob Agents Chemother 43, 1761-3 (1999)
135. Hou, L., D. Osei-Hyiaman, Z. Zhang, B. Wang, A. Yang & K. Kano: Molecular characterization of pncA gene mutations in Mycobacterium tuberculosis clinical isolates from China. Epidemiol Infect 124, 227-232 (2000)
136. Wu, X., J. Zhang & M. Zhong: [Studies on pncA gene mutations in M. tuberculosis isolates][Article in Chinese] Zhonghua Jie He He Hu Xi Za Zhi 23, 40-2 (2000)
137. Morlock, G. P., J. T. Crawford, W. R. Butler, S. E. Brim, D. Sikes, G. H. Mazurek, C. L. Woodley & R. C. Cooksey: Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother 44, 2291-5 (2000)
138. Hannan, M. M., E. P. Desmond, G. P. Morlock, G. H. Mazurek & J. T. Crawford: Pyrazinamide-monoresistant Mycobacterium tuberculosis in the United States. J Clin Microbiol 39, 647-50 (2001)
139. Park, S. K., J. Y. Lee, C. L. Chang, M. K. Lee, H. C. Son, C. M. Kim, H. J. Jang, H. K. Park & S. H. Jeong: pncA mutations in clinical Mycobacterium tuberculosis isolates from Korea. BMC Infect Dis 1, 4 (2001)
140. Lee, K. W., J. M. Lee & K. S. Jung: Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Korea. J Korean Med Sci 16, 537-43 (2001)
141. Bishop, K. S., L. Blumberg, A. P. Trollip, A. N. Smith, L. Roux, D. F. York & P. Kiepiela: Characterisation of the pncA gene in Mycobacterium tuberculosis isolates from Gauteng, South Africa. Int J Tuberc Lung Dis. 5, 952-7 (2001)
142. Bamaga, M., H. Zhang & D. J. Wright: New mutations in pncA of in vitro selected pyrazinamide-resistant strains of Mycobacterium tuberculosis. Microb Drug Resist 7, 223-8 (2001)
143. Lee, A. S., L. L. Tang, I. H. Lim & S. Y. Wong: Characterization of pyrazinamide and ofloxacin resistance among drug resistant Mycobacterium tuberculosis isolates from Singapore. Int J Infect Dis 6, 48-51 (2002)
144. Endoh, T., A. Yagihashi, N. Uehara, D. Kobayashi, N. Tsuji, M. Nakamura, S. Hayashi, N. Fujii & N. Watanabe: Pyrazinamide resistance associated with pncA gene mutation in Mycobacterium tuberculosis in Japan. Epidemiol Infect. 128, 337-42 (2002)
145. Du, X., W. Wang, R. Kim, H. Yakota, H. Nguyen & S. H. Kim: Crystal structure and mechanism of catalysis of a pyrazinamidase from Pyrococcus horikoshii. Biochemistry 40, 14166-72 (2001)
146. Scorpio, A., D. Collins, D. Whipple, D. Cave, J. Bates & Y. Zhang: Rapid differentiation of bovine and human tubercle bacilli based on a characteristic mutation in the bovine pyrazinamidase gene. J Clin Microbiol. 35, 106-10 (1997)
147. Schatz, A., E. Bugie & S. Waksman: Proc Soc Exp Biol Med 55, 66-69 (1944)
148. Davies, J. & B. D. Davis: Misreading of ribonucleic acid code words induced by aminoglycoside antibiotics. The effect of drug concentration. J Biol Chem 243, 3312-6 (1968)
149. Garvin, R. T., D. K. Biswas & L. Gorini: The effects of streptomycin or dihydrostreptomycin binding to 16S rRNA or to 30S ribosomal subunits. Proc Natl Acad Sci USA 71, 3814-3818 (1974)
150. C B Inderlied & M Salfinger: Antimycobacterial agents and susceptibility tests. In: Manuals of clinical microbiology. Eds: Murray P R, Baron E J, Pfaller M A, Tenover F C, Yolken R H, 1601-1623 (1999)
151. Kenney, T. J. & G. Churchward: Cloning and sequence analysis of the rpsL and rrsG genes of Mycobacterium smegmatis and characterization of mutations causing resistance to streptomycin. J Bacteriol 176, 6153-6156 (1994)
152. Sreevatsan, S., X. Pan, K. Stockbauer, D. Williams, B. Kreiswirth & J. M. Musser: Characterization of rpsL and rrs mutations in streptomycin- resistant Mycobacterium tuberculosis isolates from diverse geographical localities. Antimicrob Agents Chemother 40, 1024-1026 (1996)
153. Cooksey, R. C., G. P. Morlock, A. Mcqueen, S. E. Glickman & J. T. Crawford: Characterization of streptomycin resistance mechanisms among Mycobacterium tuberculosis isolates from New York City. Antimicrob Agents Chemother 40, 1186-1188 (1996)
154. Honore, N., G. Marchal & S. T. Cole: Novel mutation in 16S rRNA associated with streptomycin dependence in Mycobacterium tuberculosis. Antimicrob Agents Chemother 39, 769-70 (1995)
155. Victor, T. C., A. van Rie, A. M. Jordaan, M. Richardson, G. D. van Der Spuy, N. Beyers, P. D. van Helden & R. Warren: Sequence polymorphism in the rrs gene of Mycobacterium tuberculosis is deeply rooted within an evolutionary clade and is not associated with streptomycin resistance. J Clin Microbiol 39, 4184-6 (2001)
156. Ainsa, J. A., E. Perez, V. Pelicic, F. X. Berthet, B. Gicquel & C. Martin: Aminoglycoside 2′-N-acetyltransferase genes are universally present in mycobacteria: characterization of the aac(2′)-Ic gene from Mycobacterium tuberculosis and the aac(2′)-Id gene from Mycobacterium smegmatis. Mol Microbiol. 24, 431-441 (1997)
157. Ainsa, J. A., C. Martin, B. Gicquel & R. Gomez-Lus. Characterization of the chromosomal aminoglycoside 2′-N-acetyltransferase gene from Mycobacterium fortuitum. Antimicrob Agents Chemother 40, 2350-2355 (1996)
158. Gangadharam, P. R., P. F. Pratt, V. K. Perumal & M. D. Iseman: The effects of exposure time, drug concentration, and temperature on the activity of ethambutol versus Mycobacterium tuberculosis. Am Rev Respir Dis 141, 1478-82 (1990)
159. Takayama, K. & J. O. Kilburn: Inhibition of synthesis of
160. Wolucka, B.A., M.R. McNeil, E. de Hoffmann, T. Chojnacki & P.J. Brennan: Recognition of the lipid intermediate for arabinogalactan/arabinomannan biosynthesis and its relation to the mode of action of ethambutol on mycobacteria. J Biol Chem 269, 23328-23335 (1994)
161. Mikusova, K., R. A. Slayden, G. S. Besra & P. J. Brennan: Biogenesis of the mycobacterial cell wall and the site of action of ethambutol. Antimicrob Agents Chemother 39, 2484-9 (1995)
162. Deng, L., K. Mikusova, K. G. Robuck, M. Scherman, P. J. Brennan & M. R. McNeil: Recognition of multiple effects of ethambutol on metabolism of mycobacterial cell envelope. Antimicrob Agents Chemother 39, 694-701 (1995)
163. Zhang, N., J. B. Torrelles, M. R. McNeil, V. E. Escuyer, K. H. Khoo, P. J. Brennan & D. Chatterjee: The Emb proteins of mycobacteria direct arabinosylation of lipoarabinomannan and arabinogalactan via an N-terminal recognition region and a C-terminal synthetic region. Mol Microbiol. 50, 69-76 (2003)
164. Escuyer, V. E., M. A. Lety, J. B. Torrelles, K. H. Khoo, J. B. Tang, C. D. Rithner, C. Frehel, M. R. McNeil, P. J. Brennan & D. Chatterjee: The role of the embA and embB gene products in the biosynthesis of the terminal hexaarabinofuranosyl motif of Mycobacterium smegmatis arabinogalactan. J Biol Chem 276, 48854-62 (2001)
165. Sreevatsan, S., K. E. Stochbauer, X. Pan, B. N. Kreiswirth, S. L. Moghazeh, W. R. Jacobs, Jr., A. Telenti & J. M. Musser: Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations. Antimicrob Agents Chemother 41, 1677-1681 (1997)
166. Ramaswamy, S. V., A. G. Amin, S. Goksel, C. E. Stager, S. J. Dou, H. El Sahly, S. L. Moghazeh, B. N. Kreiswirth & J. M. Musser: Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 44, 326-336 (2000)
167. Mokrousov, I., T. Otten, B. Vyshnevskiy & O. Narvskaya: Detection of embB306 mutations in ethambutol-susceptible clinical isolates of Mycobacterium tuberculosis from Northwestern Russia: implications for genotypic resistance testing. J Clin Microbiol 40, 3810-3 (2002)
168. Drlica, K. & M. Malik: Fluoroquinolones: action and resistance. Curr Top Med Chem 3, 249-82 (2003)
169. Hu, Y., A. R. Coates & D. A. Mitchison: Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 41, 653-7 (2003)
170. Takiff, H. E., L. Salazar, C. Guerrero, W. Philipp, W. M. Huang, B. Kreiswirth, S. T. Cole, W. R. Jacobs, Jr. & A. Telenti: Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 38, 773-780 (1994)
171. Cambau, E., W. Sougakoff, M. Basson, C. Truffot-Pernot, J. Grosset & V. Jarlier: Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. J Infect Dis 170, 479-483 (1994)
172. Kocagoz, T., C. J. Hackbarth, I. Unsal, E. Y. Rosenberg, H. Nikaido & H. F. Chambers: Gyrase mutations in laboratory-selected, fluoroquinolone- resistant mutants of Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother 40, 1768-1774 (1996)
173. Alangaden, G. J., E. K. Manavathu, S. B. Vakulenko, N. M. Zvonok & S. A. Lerner: Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients. Antimicrob Agents Chemother 39, 1700-3 (1995)
174. Takiff, H. E., M. Cimino, C. M. Musso, T. Weisbrod, R. Martinez, M. B. Delgado, L. Salazar, B. R. Bloom & W. R. Jacobs, Jr.: Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis. Proc Natl Acad Sci USA 93, 362-366 (1996)
175. Liu, J., H. E. Takiff & H. Nikaido: Active efflux of fluoroquinolones in Mycobacterium smegmatis mediated by LfrA, a multidrug efflux pump. J Bacteriol 178, 3791-3795 (1996)
176. Sander, P., E. De Rossi, B. Boddinghaus, R. Cantoni, M. Branzoni, E. C. Bottger, H. Takiff, R. Rodriquez, G. Lopez & G. Riccardi: Contribution of the multidrug efflux pump LfrA to innate mycobacterial drug resistance. FEMS Microbiol Lett. 193, 19-23 (2000)
177. World Health Organization: Guidelines for establishing DOTS-Plus pilot projects for the management of multidrug-resistant tuberculosis (MDR-TB). WHO/DCS/TB/2000.279. World Health Organization, Geneva, Switzerland (2000)
178. rd: Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 97, 9677-82 (2000)
179. Baulard, A. R., J. C. Betts, J. Engohang-Ndong, S. Quan, R. A. McAdam, P. J. Brennan, C. Locht & G. S. Besra: Activation of the pro-drug ethionamide is regulated in mycobacteria. J Biol Chem 275, 28326-31 (2000)
180. Vannelli, T. A., A. Dykman & P. R. Ortiz de Montellano: The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase. J Biol Chem 277, 12824-9 (2002)
181. Taniguchi, H., B. Chang, C. Abe, Y. Nikaido, Y. Mizuguchi & S. I. Yoshida: Molecular analysis of kanamycin and viomycin resistance in Mycobacterium smegmatis by use of a conjugation system. J Bacteriol 179, 4795-4801 (1997)
182. Suzuki, Y., C. Katsukava, A. Tamaru, C. Abe, M. Makino, Y. Mizuguchi & H. Taniguchi: Detection of kanamycin-resistant Mycobacterium tuberculosis by identifying mutations in the 16S rRNA gene. J Clin Microbiol 36, 1220-1225 (1998)
183. Alangaden, G. J., B. Kreiswirth, A. Aouad, M. Khetarpal, F. R. Igno, S. L. Moghazeh, E. K. Manavathu & S. A. Lerner: Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 42, 1295-1297 (1998)
184. Prammananan, T., P. Sander, B. A. Brown, K. Frischkorn, G. O. Onyi, Y. Zhang, E. C. Bottger & R. J. Wallace, Jr.: A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae. J Infect Dis. 177, 1573-81 (1998)
185. F G Winder: Mode of action of the antimycobacterial agents and associated aspects of the molecular biology of the mycobacteria. In: The Biology of Mycobacteria. Eds: Ratledge, Stanford J, Academic Press, New York 354-438 (1982)
186. Caceres, N. E., N. B. Harris, J. F. Wellehan, Z. Feng, V. Kapur & R. G. Barletta: Overexpression of the D-alanine racemase gene confers resistance to D-cycloserine in Mycobacterium smegmatis. J Bacteriol 179, 5046-5055 (1997)
187. Feng, Z. & R. G. Barletta: Roles of Mycobacterium smegmatis D-alanine:D-alanine ligase and D-alanine racemase in the mechanisms of action of and resistance to the peptidoglycan inhibitor D-cycloserine. Antimicrob Agents Chemother 47, 283-91 (2003)
188. Chacon, O., Z. Feng, N. B. Harris, N. E. Caceres, L. G. Adams & R. G. Barletta: Mycobacterium smegmatis D-alanine racemase mutants are not dependent on D-alanine for growth. Antimicrob Agents Chemother 46, 47-54 (2002)
189. Peteroy, M., A. Severin, F. Zhao, D. Rosner, U. Lopatin, H. Scherman, A. Belanger, B. Harvey, G. F. Hatfull, P. J. Brennan & N. D. Connell: Characterization of a Mycobacterium smegmatis mutant that is simultaneously resistant to D-cycloserine and vancomycin. Antimicrob Agents Chemother. 44, 1701-4 (2000)
190. Stewart, P. S. & J. W. Costerton: Antibiotic resistance of bacteria in biofilms. Lancet 358, 135-8 (2001)
191. Zhang, Y. & L. M. Amzel: Tuberculosis drug targets. Curr Drug Targets. 3, 131-54 (2002)
192. Rosner, J.L.: Nonheritable resistance to chloramphenicol and other antibiotics induced by salicylates and other chemotactic repellents in Escherichia coli K-12. Proc Natl Acad Sci U S A 82, 8771-4 (1985)
193. Price, C. T., I. R. Lec & J. E. Gustafson: The effects of salicylate on bacteria. Int J Biochem Cell Biol 32, 1029-1043 (2000)
194. Schaller, A., Z. Sun, Y. Yang, A. Somoskovi & Y. Zhang: Salicylate reduces susceptibility of Mycobacterium tuberculosis to multiple antituberculosis drugs. Antimicrob Agents Chemother 46, 2636-9 (2002)
195. Gustafson, J. E., P. V. Candelaria, S. A. Fisher, J. P. Goodridge, T. M. Lichocik, T. M. McWilliams, C. T. Price, F. G. O'Brien & W. B. Grubb. 1999. Growth in the presence of salicylate increases fluoroquinolone resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 43:990-992.
196. Cohen, S. P., S. B. Levy, J. Foulds & J. L. Rosner: Salicylate induction of antibiotic resistance in Escherichia coli: activation of the mar operon and a mar-independent pathway. J Bacteriol 175, 7856-7862 (1993)
197. Okusu, H., D. Ma & H. Nikaido: AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic- resistance (Mar) mutants. J Bacteriol 178, 306-308 (1996)
198. McDermott, P. F., D. G. White, I. Podglajen, M. N. Alekshun & S. B. Levy: Multidrug resistance following expression of the Escherichia coli mar A gene in Mycobacterium smegmatis. J Bacteriol 180, 2995-2998 (1998)
199. nd ed., vol. 2. Eds: Kelley W N, Harris E D, Ruddy S, Sledge C B, Saunders, Philadelphia, PA (1985)
200. Wallis, R. S., S. Patil, S. H. Cheon, K. Edmonds, M. Phillips, M. D. Perkins, M. Joloba, A. Namale, J. L. Johnson, L. Teixeira, R. Dietze, S. Siddiqi, R. D. Mugerwa, K. Eisenach & J. J. Ellner: Drug tolerance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 43, 2600-6 (1999)
201. The World Health Organization Global Tuberculosis Program. http://www.who.int/gtb/
202. The Global Alliance for TB Drug Development. http://www.tballiance.org/